RecruitingNot ApplicableNCT06258707

Bicentric Clinical Investigation to Assess Safety and Performance of LuxBoost IOL

Bicentric Clinical Investigation to Assess Safety and Performance of a Hydrophobic Acrylic Enhanced Monofocal Intraocular Lens.

Sponsor

Cutting Edge SAS

Enrollment

58 participants

Start Date

Oct 14, 2024

Study Type

INTERVENTIONAL

Conditions

Aphakia

Summary

The study purpose is to demonstrate safety and performance of bilateral implantation of LuxBoost intraocular lenses compared with the LuxGood Monofocal lens.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called LuxBoost IOL and a medical device called LuxGood IOL for people with aphakia. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 50 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICELuxBoost IOL

Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.

DEVICELuxGood IOL

Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.

Locations(2)

Clinique Honore Cave

Montauban, France

West Ophta

Rennes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06258707

Related Trials

Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs

NCT071616355 locations